The Role of Glutamate Receptors in Ischemic Stroke

Qi Long, Chaoran Wu, Haowei Sun, Hong LiaoBiocell 2025 · DOI

Abstract

Glutamate is an essential excitatory neurotransmitter in the brain, playing a vital role in regulating synaptic activity and maintaining the homeostasis of the cerebral environment. However, it also serves as a central hub for neuronal death during ischemic events. This review maps the complex landscape of glutamate receptors, detailing how specific subtypes act as "double-edged swords" that can either drive cell death or activate survival pathways like PI3K/AKT and CREB.

Introduction

Ischemic stroke accounts for roughly 87% of all stroke cases and remains a leading cause of long-term disability worldwide, with 70%–80% of survivors facing significant functional impairment. While acute treatments like tissue plasminogen activator (t-PA) exist, they have narrow therapeutic windows.

The fundamental challenge in treating stroke is "excitotoxicity." When blood flow is blocked, neurons dump massive amounts of glutamate into the synaptic cleft. This overstimulates receptors, causing a lethal influx of calcium ($Ca^{2+}$) and a cascade of oxidative stress. However, simply blocking all glutamate receptors has failed in clinical trials because these receptors are also essential for normal brain function and post-stroke repair. This review aims to clarify which specific receptor pathways lead to injury versus those that promote neuroprotection and rehabilitation.

The Glutamate Receptor Landscape

Glutamate receptors are categorized into two main families, each with distinct downstream signaling effects:

  • Ionotropic Glutamate Receptors (iGluRs): Fast-acting ion channels, including N-methyl-D-aspartate receptors (NMDARs), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), and kainate receptors (KARs).
  • Metabotropic Glutamate Receptors (mGluRs): Slower G-protein-coupled receptors divided into Groups I, II, and III.

The structural differences within these families, such as the NR2A versus NR2B subunits of NMDARs, determine whether a receptor promotes cell survival or programmed death.

The NMDAR Paradox: Survival vs. Death

NMDAR activation is not inherently pathological. The review highlights that the outcome of NMDAR signaling depends on location and subunit composition:

  • Synaptic NMDARs: Often containing the NR2A subunit, these receptors typically activate pro-survival pathways like PI3K/AKT and CREB.
  • Extrasynaptic NMDARs: Frequently containing the NR2B subunit, these are more likely to trigger cell death via DAPK1 and nNOS signaling.

Temporal Dynamics of AMPARs and mGluRs

The role of AMPA receptors changes over time. While early overactivation contributes to the initial infarct, delayed enhancement of AMPA signaling is actually crucial for behavioral recovery and sensorimotor function during the rehabilitation phase.

Metabotropic receptors (mGluRs) act as the system's fine-tuners. Group II and III mGluRs generally act as "brakes," inhibiting further glutamate release. This makes them attractive targets for neuroprotection with potentially fewer side effects than total NMDAR blockade.

The Astrocyte Factor

Astrocytes are active participants in regulating the cerebral environment. They express mGluR5 and EAAT2 transporters to mop up excess glutamate. Interestingly, mGluR5 expression, which normally declines in adults, is "re-expressed" after a stroke to help facilitate circuit regeneration and the brain's natural recovery processes.

The Molecular Death Cascade

The review summarizes the molecular sequence triggered by ischemia:

  1. Ischemia/Hypoxia: ATP depletion leads to ion pump failure.
  2. Glutamate Surge: Overactivation of NMDARs and AMPARs occurs.
  3. Calcium Overload: This triggers the activation of Calpain (proteases) and nNOS (nitric oxide production).
  4. Mitochondrial Dysfunction: The release of apoptotic factors and reactive oxygen species (ROS) leads to neuronal death.

Limitations and Future Directions

A major "translational gap" exists in stroke research; numerous NMDAR antagonists that were effective in animal models failed in human trials due to severe side effects like psychosis and cognitive impairment.

Future directions include developing subunit-specific drugs that target "death-promoting" subunits (like NR2B) while sparing "survival-promoting" ones (like NR2A). Additionally, shifting focus toward glial-targeted therapies and better defining the therapeutic windows for receptor inhibition versus stimulation will be critical for moving treatments from the lab to the clinic.

Summary updated

Abstract

Glutamate is an essential excitatory neurotransmitter in the brain, playing a vital role in regulating synaptic activity and maintaining the homeostasis of the cerebral environment but also serves as a central hub for neurona... | Find, read and cite all the research you need on Tech Science Press
BibTeX
@inproceedings{long2025role,
  author = {Qi Long and Chaoran Wu and Haowei Sun and Hong Liao},
  title = {{The Role of Glutamate Receptors in Ischemic Stroke}},
  booktitle = {Biocell},
  year = {2025},
  doi = {10.32604/biocell.2025.059159},
}
Figure